Amblyopia
Abstract
Background: Amblyopia mens weaker visual acuity of one or both eyes and is not due to an organic leason. It usually develops in early childhood, patients 8 years or older with a normal visual system have low probability of developing amblyopia. There is a risk of reappearing amblyopia even after it had been treated till the age of 9 or 10. The most frequent reason for developing amblyopia are strabismus, amethropia and anisomethropia.
Conclusions: The treatment of amblyopia is removal of the source, prescription of suitable correction of refractive error, occlusion of the healthier eye, pleoptic exercises and surgical treatment if necessary. Early identification of amblyopia is important for a good treatment outcome.
Downloads
References
Newman DK, East MM. Prevalence of amblyopia among defaulters of preschool vision screening. Ophthalmic Epidemiol 2000; 7: 67–71.
Attebo K, Mitchell P, Cumming R, Smith W, Jolly N, Sparkes R. Prevalence and causes of amblyopia in an adult population. Ophthalmology 1998; 105: 154–9.
Simons K. Amblyopia characterization, treatment, and prophylaxis. Surv Ophthalmol 2005; 50: 123–66.
Ohlsson J, Villarreal G, Sjostrom A, Abrahamsson M, Sjostrand J. Visual acuity, residual amblyopia and ocular pathology in a screened population of 12–13-year-old children in Sweden. Acta Ophthalmol Scand 2001; 78: 589–95.
Eibshitz-Tsimhoni M, Friedman T, Naor J, Eibschitz N, Friedman Z. Early screening for amblyogenic risk factors lowers the prevalence and severity of amblyopia. J AAPOS 2000; 4: 194–9.
Kosec D. Amblyopia. Slov Pediatr 2000; 7: 35–6.
Keech RV, Kutschke PJ. Upper age limit for the development of amblyopia. J Pediatr Ophthalmol Strabismus 1995; 32: 89–93.
Diamond GR. Amblyopia. In: Yannof Duker JS, eds. Ophthalmology. 2nd edition. St. Louis: Mosby; 2004. p. 615–25.
Pratt-Johnsson JA, Tillson G. Management of strabismus and amblyopia: A practical guide. New York: Thieme; 1994.
Kessel L, Hougaard JL, Mortensen C, Jorgensen T, Lund-Andersen H, Larsen M. Visual acuity and refractive errors in a suburban Danish population: Inter 99 eye study. Acta Ophthalmol Scand 2004; 82: 19–24.
Shaw DE, Fielder AR, Minshull C, Rosenthal AR. Amblyopia – factors influencing age of presentation. Lancet 1988; 2: 207–9.
J Pediatric Eye Disease Investigator Group. The clinical profile of moderate amblyopia in children younger than 7 years. Arch Ophthalmol 2002; 120: 281–7.
Sjostrand B, Abrahamsson M. Can we identify risk groups for the development of amblyopia and strabismus? Klin Monatsbl Augenheilkd 1996; 208: 23–6.
Sjostrand B, Abrahamsson M. Risk factors in amblyopia. Eye 1990; 4: 787–93.
Abrahamsson M, Magnusson G, Sjostrand J. Inheritance of strabismus and gain of using heredity to determine populations at risk of developing strabismus. Acta Ophthalmol Scand 1999; 77: 653–7.
Birnbaum MH, Koslowe K, Sanet R. Success in amblyopia therapy as a function of age: a literature survey. Am J Optom Physiol Opt 1977; 54: 269–75.
Kutschke PJ, Scott WE, Keech RV. Anisometropic amblyopia. Ophthalmology 1991; 98: 258–63.
Leguire LE, Regan GL, Bremer DL, Walson PD, McGregor ML. Levodopa/ carbidopa for childhood amblyopia. Invest Ophthalmol Vis Sci 1993; 34: 3090–5.
Gottlob I. The detection, prevention, and rehabilitation of amblyopia. Curr Opin Ophthalmol 1999; 10: 300–4.
Fletcher MC, Abbott W, Girard LJ, Guber D, Silvermann SJ, Tomlinson E, Boyd J. Results of biostatistical study of the management of the suppression amblyopia by intensive pleoptics versus conventional patching. Am Orthopt J 1969; 19: 8–30.
Ohlsson J, Baumann M, Sjostrand J, Abrahamsson M. Long term visual outcome in amblyopia treatment. Br J Ophthalmol 2002; 86: 1148–51.
Ching FC, Parks MM, Friendly DS. Practical management of amblyopia. J Pediatr Ophthalmol Strabismus 1986; 23: 12–6.
Scott WE, Dickey CF. Stability of visual acuity in amblyopic patients after visual maturity. Graefes Arch Clin Exp Ophthalmol 1988; 226: 154–7.
Leiba H, Shimshoni M, Oliver M, Gottesman N, Levartovsky S. Long-term follow-up of occlusion therapy in amblyopia. Ophthalmology 2001; 108: 1552–5.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
